C urrent practice guidelines for the treatment of patients with schizophrenia suggest a combination of antipsychotic medication plus individual and family interventions, especially psychoeducation. 1 Psychoeducation has a component that is aimed at reducing expressed emotion (i.e., the level of a ''family_s criticism of and involvement with or support for the identified patient'') and, in combination with other family interventions, are associated with better long-term outcomes.
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The crucial issue, of course, is that, in part, these family variables are thought to be mediating variables related to antipsychotic medication adherence, and degree of adherence is positively correlated to outcome. 5 The difficulty of working with a chronic psychotic patient is well known, especially those patients with sporadic substance abuse/dependence. However, what is not clear is whether medication can be effective if there is no family involved or, if present, the patient-family interaction prevents them from being supportive. In fact, in practice, this issue is usually not appreciated or even commonly part of the clinical calculation of whether effective treatment is even possible.
Unexpectedly, CATIEVthe recent, large-scale, multi-site National Institute of Mental Health trial of effectiveness of antipsychotics, provided the opportunity to examine the issue of the relationship of family support to drug compliance and outcome. 6 The CATIE study was designed to keep families involved throughout treatment using an individually tailored education plan. The study focused on ''all cause discontinuation'' as the single, best outcome measure of effectiveness 6 but had other secondary outcome measures as well. As one of the CATIE sites with a large number of enrolled subjects, as we progressed, we noted 2 patterns of patient discontinuation or dropout. Patients either had families with low support and/or high conflict or had no family at all, and both patterns seemed to be associated with either early dropout or worse outcomes compared with the rest of our sample. Accordingly, after the study ended, we decided to systematically examine these family variables at our site to determine the correlation, if any, with outcome.
Post hoc, we hypothesized that the presence of a family and/or a relatively higher level of family ''support'' especially for ''medication adherence'' correlated positively with better outcomes and vice versa. Conversely, not having a family or having lower levels of availability/support were predicted to correlate with early dropout and/or worse outcomes. Although the crucial role of the family in improving outcome of patients with schizophrenia has been well studied, described, and included in most American Psychiatric Association and other guidelines, commonly patients on antipsychotic medication are prescribed drugs and managed without regular and continuous family involvement. We recognize, of course, that there are many practical reasons for this lack of involvement. A patient may not have any family (broadly defined), or if they do, the patient-family interaction patternsVespecially during the acute phases of the illness when patients may be fearful and paranoidVmay prevent the family from being supportive or working collaboratively.
The central question is whether it is possible to achieve reasonable outcomes without a family, specifically a supportive family, regardless of good medication practices. This study examines this question.
METHODOLOGY Study Setting and Design
The CATIE study was initiated by the National Institute of Mental Health to compare the relative effectiveness of antipsychotic drugs over 18 months in 3 phases with all-clause discontinuation as the primary outcome measure. 6 Of note to this report, the CATIE design specifically included regular, ongoing family education and psychoeducation using a specially designed, detailed manual for the study. Further design details can be found in the 2003 publication.
Subjects
Inclusion criteria required all participants to have a formal diagnosis of schizophrenia as determined by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and to be between the ages of 18 and 65 years. As one of the largest enrollers in CATIE, our study group consisted of the 50 patients randomized at our site. Demographically, our sample was representative of the multisite CATIE sample. Table 1 lists the demographics of those patients who were discontinued/dropped out and were unimproved/worse. Most had chronic schizophrenia. Most were white male subjects, single or divorced, with a mean age of 35 years, mode 22. Two of the patients regularly abused marijuana. Forty of the 50 had families, or significant others involved to varying degrees. Thirty-three of 50 patients completed either Phase I or II of the study; the other 17 were early dropouts or discontinued.
Evaluation
There were a wide range of efficacy, effectiveness, and safety ratings embedded in the CATIE study. For this report, post hoc our treatment team, by group consensus, used the data we collected about treatment course and family patterns at the time of study enrollment and over the course of study visits, to divide the 50 families into 2 groups. The first group had a family/significant other, available and mostly supportive, to work collaboratively to facilitate adherence with the treatment team (n = 27). The second group was more heterogeneousVeither they did not have the family/significant other support because there was no one available (the patient was essentially on his own, n = 10), or more commonly, the patient-family unit were in a highly conflicted struggle (usually because the patientusually in his 20s or early 30sVwas psychotic and irritable), or the family would not/could not come in regularly for treatment visits. By way of case description, we refer to this group as ''nonsupportive,'' but obviously, this phrase does not entirely capture the complexity of the patient-family interaction (or lack of it). Nevertheless, the distinction between groups was marked.
Also, at the conclusion of the study, for patients who were randomized, we made a global rating of outcome at the time of their dropout or at the time they finished with the study. This assessment was dichotomized into improved versus no change or worsened at the end of their duration in the study. Here, we used not only our treatment team ratings of outcome but also, because our rating may have been biased, the outcome ratings in the CATIE database (see below) which come from blinded raters. We recognize the rating of ''unimproved or worse'' was partially artificially inflated by those patients who dropped out as well as those who stayed in the study and did not improve.
Finally, we correlated study completion and outcome with the 2 patient-family groupings.
Although our focus was on family presence and supportVthe CATIE evaluative measures included a global measure (the Clinical Global Impression [CGI]) and a Quality of Life (QOL) assessment derived from information from the patient. We examined QOL data in the context of understanding our results. The QOL is a 31-item scale with multiple questions assessing an individual_s perception of their degree of enjoyment and satisfaction experienced in everyday life. The QOL assessment included several questions that indirectly spoke to the level of family support. One of the questions was: ''In the past month, how often did you spend time with one or more family members?'' Patient choices included being reminded of appointments, being taken to appointments, being reminded to take medication, and being given their medication. These questions were not originally intended to be used as a measure for level of family support; however, they seem to capture a significant 
Data Analysis
The Pearson W 2 test of independence was used to measure the association between the family variables and the patient outcome variables, that is, study completion and improvement.
RESULTS

Remaining in Treatment
The first question addressed was whether having a supportive family (versus either not having a family or the family not being available or the interaction being conflicted) is associated with treatment completion. Table 2 reveals that of the 27 patients with supportive families, 23 (85%) remained in treatment for the entire study. In contrast, 13 (56%) of the 23 patients of the second group dropped out (P G 0.01).
Treatment Outcome
The next issue is whether having a supportive family is associated with better global outcome. Table 3 reveals that 24 (89%) of the 27 patients with such families improved. On the other hand, 14 (61%) of the 23 patients of the nonavailable/ nonsupportive group showed no change or worsened postbaseline (P G 0.001). We also ran this analysis using the all-cause discontinuation rates for the 48 patients from the CATIE data base. Here, the results were the sameVW 2 1 was 11.7, P G 0.001.
Patient and Family Contact and Compliance
To better understand these findings, we examined the correlation of family support with CGI and QOL scales. Interestingly, the less the patient improved (as shown on the CGI), the more the patient-family contact. Our interpretation was that when patients were doing badly, that is, psychotic or more symptomatic or irritable, they required more family help. On the QOL scale, we found, in fact, that when the patients were doing well, they had (as expected) less contact with the family. The QOL item on family contact and medication compliance showed that patient improvement correlated with the family_s help in taking medication.
DISCUSSION
Using the patient sample from our site, a subsample from a large-scale, multisite study of the effectiveness of antipsychotics, we found having both a family (and even more importantly, their being supportive of adherence), positively was associated not only with study completion but also with good outcome. These findings are consistent with the literature suggesting the importance of a ''supportive family environment'' for patients with schizophrenia. 5 In fact, family interventions have been found to improve medication compliance and reduce relapse rates by approximately 20%. 5 Likewise, medication compliance is improved when patients have help from family caregivers. 7 On the other hand, not having a family 8 or having a nonsupportive/ available/conflicted family situation was associated with early termination and poorer outcome. Examining these family units, we found that usually the problem was that either the patient (usually in his 20s or early 30s) was psychotic, paranoid, and/or irritable when interacting with the family, or if older, the family stayed away, that is, ''worn-out'' from trying to help their chronically ill child or spouse. These outcomes seemed true regardless of which antipsychotic the patient was taking (although post hoc we did not, and could not, because of lack of statistical power to examine this question).
There are a number of limitations to our study. First, this was not a prospective, controlled, double-blind, random assignment study focusing on the family. It was a correlative study; therefore, it is not clear what is the cause and what is the effect. For example, nonsupportive families could have seemed to be so because of the patient_s problematic, symptomatic behaviors (being irritable or psychotic) or nonresponse to treatment. In fact, all of the patient-family units, who were judged ''antagonistic'' or nonsupportive with high expressed emotion, had identified patient spouses or children who were psychotic, denied their illness, and/or refused medication. Our impression was that the family_s behavior remained relatively consistent from the study onset, and as we noted (above), the more the family contact, usually the worse the patient was doing. Second, the number of subjects was small (compared with a prospective, random assignment efficacy study), although relatively large for studies involving families of patients with schizophrenia. Furthermore, our results are very consistent with the family literature suggesting that the results are valid. Third, although we were able to accurately determine dropout/discontinuation, there may have been bias in our nonblinded judgment of each ''family_s support level'' and of patient outcome as we rated retrospectively (although to us the judgments seemed relatively straightforward and were consistent with the CATIE data recorded from blind raters). Finally, which antipsychotic a patient was taking might have confounded these findingsValthough this seemed unlikely, given the efficacy findings from CATIE.
In summary, in the context of a large medication trial, we have found data suggesting that, regardless of the patient symptoms, having a supportive ''family,'' able to work collaboratively with the treatment team from the onset of treatment through stabilization, improves outcome. Simply put, without a supportive family, patients will not stay on their medication or remain in treatment even in well-staffed settings. These data are consistent with the recent schizophrenia guidelines for family education and psychoeducation. 1 Although this finding may not be totally new, in the context of medication adherence, it is at the very least, an important replication.
Further research on these issues is needed because it might be that family presence and support are even more important for medication adherence and outcome than what is currently believed (i.e., adequate medication is usually considered as (by far) the most crucial element in the treatment equation). Although this statement is still true, the ''family'' provides the context for the medication maintenance. The message for those prescribing antipsychotic medication isVit may be that it is necessary (almost mandatory) for patients with schizophrenia to have a supportive family or friend or case worker with relatively low ''expressed emotion'' or conflict in the family to achieve and maintain stabilization and a reasonably good longer-term outcome. It is possible that too much patient/family contact is ''toxic,'' but this is not clear from our findings. This may be true, regardless of which antipsychotic is prescribed. This also may be true for disorders other than schizophrenia such as bipolar disorder, in which patients are cognitively impaired with mood elevation and/or grandiosity and would need family help to adhere to treatment and to function. 9, 10 
